These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 19430004)
1. New paradigms in gastrointestinal stromal tumour management. Blay JY Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004 [TBL] [Abstract][Full Text] [Related]
2. Optimal use of targeted agents for advanced gastrointestinal stromal tumours. Reichardt P Oncology; 2010; 78(2):130-40. PubMed ID: 20389135 [TBL] [Abstract][Full Text] [Related]
3. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458 [TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
5. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Italiano A; Bui B Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576 [TBL] [Abstract][Full Text] [Related]
7. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621 [TBL] [Abstract][Full Text] [Related]
8. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107 [TBL] [Abstract][Full Text] [Related]
10. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647 [TBL] [Abstract][Full Text] [Related]
11. C-kit, GIST, and imatinib. Siehl J; Thiel E Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922 [TBL] [Abstract][Full Text] [Related]
13. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib]. Nishida T; Omori T; Ueshima S Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Li J; Gao J; Hong J; Shen L Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424 [TBL] [Abstract][Full Text] [Related]
16. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Blay JY; Reichardt P Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720 [TBL] [Abstract][Full Text] [Related]
17. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751 [TBL] [Abstract][Full Text] [Related]
18. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278 [TBL] [Abstract][Full Text] [Related]
19. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]